Clinical trials: Hepatic Neoplasm
Carcinoma, Hepatocellular
A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular…
- Trial name
- RELATIVITY-106 (NCT05337137)
- Testing
- Relatlimab, Nivolumab, Bevacizumab
- Where
- 61 sites in United States, Australia and 13 more
- Volunteers
- 82 people
- Sponsor
- Bristol-Myers Squibb
Liver Cancer, Lung Cancer
Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors
Tumor infiltration lymphocytes (TILs) have been harvested from advanced cancer patients and constructed to knockout PD1 gene and express scFvs against both PD1 and CTALA4 and CARs against various antigens, followed by transfusion…
- Conditions
- Liver Cancer, Lung Cancer, Breast Cancer, Colo-rectal Cancer
- Trial name
- NCT04842812
- Testing
- TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Precision Cell Immunotherapy, Transcatheter Arterial Chemoembolization
Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer
To evaluate the safety and effectiveness of cell therapy using precision cells Combined With TACE in Advanced Liver Cancer. Eligibility: Individuals greater than or equal to 18 years of age and less than or equal to 65 years of…
- Conditions
- Precision Cell Immunotherapy, Transcatheter Arterial Chemoembolization, Advanced Liver Cancer
- Trial name
- NCT02873442
- Testing
- TACE, Precision Cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ningbo Cancer Hospital
HCC - Hepatocellular Carcinoma
Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVI
Tumor recurrence is the leading cause of death and a major bottleneck for long-term survival in patients with hepatocellular carcinoma (HCC).
- Trial name
- Ad-rHCC (NCT07658105)
- Testing
- eparlitozoviril, Control group
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Colorectal Neoplasms
FOLFOXIRI-based HAIC Combined With Fuquintinib as Late-line Treatment in Patients With CRLM：A Phase 2 Single-Arm Clinical Trial
This study was a phase 2, single-arm, single-center clinical trial in which previously treated patients with unresectable colorectal cancer liver metastases.
- Trial name
- HAIC，CRLM (NCT07024537)
- Testing
- FOLFOXIRI-based HAIC+Fuquinitinib
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Meng Qiu
Colon Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma
Characterization of Mechanical Tissue Properties in Patients With Pancreatic, Liver, or Colon Cancer
This pilot research trial studies characterization of mechanical tissue properties in patients with pancreatic, liver, or colon cancer.
- Conditions
- Colon Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Pancreatic Carcinoma
- Trial name
- NCT03137706
- Testing
- Biospecimen Collection, Laboratory Biomarker Analysis, Laboratory Procedure
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Southern California
Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization
Estimation and Prediction of Individual Benefit From Postoperative Adjuvant Transcatheter Arterial Chemoembolization For Patients With Hepatocellular Carcinoma
Adjuvant transarterial chemoembolization (TACE) is widely adopted in China for resectable hepatocellular carcinoma (HCC), yet its efficacy remains inconsistent.
- Conditions
- Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization, Adjuvant Therapy, Machine Learning
- Trial name
- HCC (NCT07562763)
- Where
- China
- Volunteers
- 1,005 people
- Sponsor
- Anhui Provincial Hospital
Liver Neoplasms
Lung Dose in Patients Treated With Yttrium-90 for Hepatocellular Carcinoma
To Calculate the amount radiation the lung receives in patients receiving Yttrium-90 for Liver Cancer.
- Trial name
- NCT02489838
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Alan Katz
Hepatocellular Carcinoma, Liver Cancer
A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma
This study is for people with cancer of the liver that cannot be completely removed by surgery. This study involves giving the drugs mitomycin-C and cisplatin, into an artery in the liver.
- Trial name
- NCT00183885
- Testing
- mitomycin-c, cisplatin
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- University of Southern California
Hepatocellular Carcinoma
Combination PET With 18F-fluorodeoxyglucose (18F-FDG) and 18 F-choline in Patient With HCC
The objective of this protocol is to obtain a better match between the actual staging and the proposed treatment in order to avoid inadequate treatments at risk of complications.
- Trial name
- PET-HCC01 (NCT04391348)
- Testing
- PET-TDM with 18F-FDG + PET-TDM with 18F-fluorocholine
- Where
- France
- Volunteers
- 230 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Metabolic Dysfunction-Associated Steatotic Liver Disease, Hepatocellular Carcinoma
Prognostic Factors for HCC and Liver Transplantation in Patients With MASLD/MASH
The BOMASH study is a single-center, prospective/retrospective observational study without pharmacological interventions. It will include all patients diagnosed with Metabolic-Associated Steatotic Liver Disease (MASLD/MASH)…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Hepatocellular Carcinoma, Metabolic Dysfunction-Associated Steatohepatitis, Liver Transplant
- Trial name
- BOMASH (NCT06813508)
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hepatocellular Carcinoma, Hepatitis B Virus
Effects of Antiviral Therapy on Patients With HBV-related HCC
Based on the follow-up data of patients who underwent hepatectomy for HBV-related HCC at the First Affiliated Hospital of Xi'an Jiaotong University.
- Conditions
- Hepatocellular Carcinoma, Hepatitis B Virus, Survival
- Trial name
- NCT05406089
- Testing
- Medication history
- Volunteers
- 494 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Hepatocellular Carcinoma (HCC)
STRATHEP: AI-Driven Treatment Stratification for Advanced Hepatocellular Carcinoma
STRATHEP develops and validates a multimodal AI model to predict treatment response in advanced hepatocellular carcinoma. By integrating digital pathology and MRI radiomics, the project identifies patients likely to benefit from…
- Trial name
- STRATHEP (NCT07863258)
- Where
- 5 sites in Belgium
- Volunteers
- 280 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Hepatocellular Carcinoma
Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection
This study is a prospective non-randomized controlled study. The purpose of this study is to evaluate the validity and safety of sorafenib and transcatheter arterial chemoembolization (TACE) for microvascular invasion (MVI) in…
- Trial name
- NCT02537158
- Testing
- Sorafenib, TACE
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Chinese Academy of Medical Sciences
Hepatocellular Carcinoma, Pancreas Cancer
Scheduled Meditation for Improving Postoperative Outcomes in Patients Undergoing Pancreatectomy
This clinical trial tests the feasibility and how well a scheduled meditation intervention works to improve postoperative outcomes such as pain, anxiety, insomnia, stress and mobility for patients undergoing pancreatectomy.
- Conditions
- Hepatocellular Carcinoma, Pancreas Cancer, Biliary Tract Neoplasms
- Trial name
- NCT07608458
- Testing
- Actigraphy, Online Mindfulness Meditation, Smartphone Application-based Intervention
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- City of Hope Medical Center
Primary Liver Cancer
Precision Dietary Intervention Improves Postoperative Energy Intake, Nutritional Status, and Recovery in Patients Undergoing Hepatectomy for Liver Cancer: A Randomized Controlled Trial
Objective:To explore the application effect of postoperative refined early dietary plan in the enhanced recovery of patients undergoing hepatectomy for primary liver cancer, and to provide scientific evidence for optimizing…
- Trial name
- NCT07349576
- Testing
- Special diet plan and whole protein preparation NUTRICIA for 5 days after liver resection for liver cancer, Conventional dietary intervention
- Where
- China
- Volunteers
- 139 people
- Sponsor
- Anhui Provincial Hospital
Liver Cancer
Chemoembolisation of Hepatocellular Carcinomas Not Subject to Interventive Care by Idarubicin-loaded Beads - IDASPHERE II
The most frequently used products in CHE are doxorubicin (36%), cisplatin (31%), and epirubicin (12%). But until recently, there were no obvious reasons to use one product over another.
- Trial name
- IDASPHERE II (NCT02185768)
- Testing
- idarubicin, Dc- Beads 300-500µm
- Where
- 7 sites in France
- Volunteers
- 46 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Colorectal Cancer Liver Metastases (CRLM), Colorectal Cancer
Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases
This is a prospective, single-center, single-arm exploratory clinical study designed to evaluate the efficacy and safety of hepatic arterial infusion of liposomal irinotecan combined with systemic oxaliplatin and capecitabine as…
- Conditions
- Colorectal Cancer Liver Metastases (CRLM), Colorectal Cancer, Liver Metastasis
- Trial name
- NCT07570914
- Testing
- Liposomal Irinotecan, Oxaliplatin, Capecitabine
- Volunteers
- 28 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
HCC
Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model
Primary liver cancer is one of the most common malignant tumors in the world, and about 80%~90% of primary liver cancers are pathologically characterized as hepatocellular carcinoma (HCC).
- Trial name
- NCT06420440
- Testing
- Hepatic arterial infusion chemotherapy, Lenvatinib, Tislelizumab
- Where
- 2 sites in China
- Volunteers
- 160 people
- Sponsor
- Chen Xiaoping
Hepatocellular Carcinoma
A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
The efficacy and safety of AK104 as adjuvant therapy in hepatocellular carcinoma of high recurrence risk after curative resection.
- Trial name
- NCT05489289
- Testing
- AK104
- Where
- China
- Volunteers
- 570 people
- Sponsor
- Akeso
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.